Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ambea ABCHIX:AMBEAS 83 EV-to-EBITDA is 8.06 as of Jul. 25, 2026, which is 10% below its 10-year median of 8.99. GuruFocus rates CHIX:AMBEAS with a GF Score™ of 83/100 and a GF Value™ of kr123.79 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 507 Healthcare Providers & Services companies, Ambea AB ranks better than 65.88% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ambea AB's enterprise value is kr24,452 Mil.
Ambea AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr3,033 Mil. Therefore, Ambea AB's EV-to-EBITDA for today is 8.06.
The historical rank and industry rank for Ambea AB's EV-to-EBITDA or its related term are showing as below:
CHIX:AMBEAs'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.72 Med: 8.99 Max: 20.96
Current: 8.06
During the past 12 years, the highest EV-to-EBITDA of Ambea AB was 20.96. The lowest was 6.72. And the median was 8.99.
CHIX:AMBEAs's EV-to-EBITDA is ranked better than 65.88% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 10.92
vs CHIX:AMBEAs: 8.06
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Ambea AB (CHIX:AMBEAs) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ambea AB's share price for today is kr144.20.
Ambea AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr8.530.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Ambea AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:AMBEAS vs HCA, THC, DVA: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Ambea AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ambea AB EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Ambea AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ambea AB's EV-to-EBITDA falls into.
Ambea AB's current Enterprise Value is kr24,452 Mil.
Ambea AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr3,033 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ambea AB (CHIX:AMBEAS) has a EV-to-EBITDA of 8.06 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ambea AB. This is 10% below median its historical median of 8.99. Over the past decade, Ambea AB's EV-to-EBITDA has ranged from 6.72 to 20.96. According to the industry distribution chart, Ambea AB ranks #173 out of 507 companies in the Healthcare Providers & Services industry, placing it in the top 34.1%.
Is Ambea AB's EV-to-EBITDA too high?
Ambea AB's current EV-to-EBITDA of 8.06 is 10% below median its 10-year median of 8.99. Over the past 10 years, this metric has ranged from a low of 6.72 to a high of 20.96. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.92. Ambea AB's value of 8.06 is 26.2% below this industry median. Based on the distribution chart, Ambea AB ranks #173 out of 507 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Ambea AB has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ambea AB's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Ambea AB ranks #173 out of 507 companies for EV-to-EBITDA. This puts Ambea AB in the upper half of its industry. The industry median EV-to-EBITDA is 10.92. Ambea AB's value of 8.06 is 26.2% below this benchmark. Historically, Ambea AB's own EV-to-EBITDA has ranged from 6.72 to 20.96 over the past decade. While the company's 10-year median is 8.99 vs. the industry median of 10.92, Ambea AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.92, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ambea AB's current EV-to-EBITDA of 8.06 is 26.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ambea AB. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ambea AB's current EV-to-EBITDA is 8.06, which is 10% below median its own 10-year median of 8.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ambea AB stock overvalued right now?
Based on GuruFocus' analysis, Ambea AB (CHIX:AMBEAS) is currently considered Modestly Overvalued. The stock's GF Value™ is kr123.79, compared to a current price of kr144.20 — trading 16.5% above its estimated fair value. The current EV-to-EBITDA is 8.06, which is 10% below median its 10-year median of 8.99 and 26.2% below the Healthcare Providers & Services industry median of 10.92. Ambea AB's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ambea AB (CHIX:AMBEAS), the current EV-to-EBITDA is 8.06 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ambea AB (CHIX:AMBEAS) Overvalued in 2026?
Based on GuruFocus' analysis, Ambea AB stock appears to be overvalued.
The current stock price of kr144.20 is trading 16.5% above its estimated GF Value™ of kr123.79.
GuruFocus considers Ambea AB to be Modestly Overvalued.
Key valuation signals for CHIX:AMBEAS:
EV-to-EBITDA: 8.06 (10% below median its 10-year median of 8.99)
GF Value™: kr123.79 vs. price of kr144.20 (16.5% above fair value)
Industry Position: 26.2% below the Healthcare Providers & Services median (#173 of 507)
No single metric tells the full story. See the CHIX:AMBEAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ambea AB is a Swedish care-provider group focused on elderly care, disability care, psychosocial support, housing, staffing, and training across the Nordic region. The company's segment includes: i) Nytida: Comprises social care services for children, youth and adults, in Sweden, ii) Vardaga: Comprises nursing homes and home care in Sweden, iii) Stendi: Comprises social care for children, youth and adult in Norway, iv) Validia: Comprises social care for children, v) Altiden: Comprises social care for children, youth and adults as well as elderly care in Denmark, and vi) Klara: Comprises competence and staffing solutions for elderly and social care, and student health services in Sweden. The majority of the company's revenue is derived from the Vardaga segment.
83GF Score
Get the complete analysis for CHIX:AMBEAS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMBEAS has been successfully added to your 
